Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Cardiol. Dec 26, 2014; 6(12): 1245-1251
Published online Dec 26, 2014. doi: 10.4330/wjc.v6.i12.1245
Published online Dec 26, 2014. doi: 10.4330/wjc.v6.i12.1245
Experimental models of inherited cardiomyopathy and its therapeutics
Miki Nonaka, Sachio Morimoto, Department of Clinical Pharmacology, Kyushu University Graduate School of Medicine, Fukuoka 812-8582, Japan
Author contributions: Nonaka M wrote the manuscript and designed figures; Morimoto S revised the manuscript and figures; all authors read and approved the final version of the manuscript.
Supported by Grants-in-Aid for Science Research from the Japan Society for the Promotion of Science (JSPS), Nos. 25670130 and 23300145
Correspondence to: Sachio Morimoto, PhD, Department of Clinical Pharmacology, Kyushu University Graduate School of Medicine, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan. morimoto@med.kyushu-u.ac.jp
Telephone: +81-92-6416081 Fax: +81-92-6426084
Received: May 26, 2014
Revised: July 8, 2014
Accepted: October 14, 2014
Published online: December 26, 2014
Revised: July 8, 2014
Accepted: October 14, 2014
Published online: December 26, 2014
Core Tip
Core tip: Current experimental models of inherited cardiomyopathies (hypertrophic cardiomyopathy, dilated cardiomyopathy and restricted cardiomyopathy), including genetically-manipulated mouse models (transgenic and knock-in mice) and patient’s induced pluripotent stem cell-derived cardiomyocyte models, are summarized and discussed with a focus on revealed molecular pathogenic mechanisms and potential drug therapeutics.